Department of Medical Microbiology, St.
George's Hospital Medical School, London SW17 0RE, United Kingdom
 |
INTRODUCTION |
Tuberculosis is an important
infectious disease, with over 1 billion people subclinically infected
and the 3 million new cases each year resulting in 7% of the total
number of deaths (20). Case finding and treatment are the
main control measures, but chemotherapy takes 6 months to achieve a
cure because bacteria persist during chemotherapy and cause relapse (2 to 5% in 5 years) after the end of treatment (14). These
persistent bacteria are usually drug sensitive at relapse, and so their
resistance to chemotherapy is phenotypic (17) (or tolerant)
rather than genetic. It is suggested that an altered physiological
state of persistent Mycobacterium tuberculosis accounts for
its tolerance to drugs as well as the ability to survive in the host
for many years. Persistence is likely to be a combined effect of both
the immune system and bacterial physiology, resulting in what is
generally referred to as a latent state (1). A key question
is whether the metabolism of persistent bacteria is switched off with
no cell division (spore-like) or, alternatively, is active
(30).
The first major advance in the detection of quiescent M. tuberculosis was the development of the Cornell mouse model
(25). In this model, animals are infected with M. tuberculosis and treated for 3 months with chemotherapy which
renders the tissues sterile; then steroids are administered, which
leads to relapse in a high proportion of the mice. Immediately after
the end of antibiotic therapy, the persistent bacteria are invisible by
microscopy and are uncultivable, but about 105 genome
equivalents of M. tuberculosis DNA per ml of tissue in the
organs have been detected by DNA amplification (4). The presence of DNA could be indicative of dead bacilli or, possibly, of
live bacilli which can multiply when the host immune system becomes
weakened by steroids. Since DNA can be detected in dead bacteria
(9, 16, 24), targeting genomic DNA is not suitable for the
determination of metabolic activity and viability of bacteria.
It has been suggested that the presence of rRNA could be an indicator
of viability in M. smegmatis (33),
Escherichia coli (26, 32), and
Staphylococcus aureus (26), although the
correlation of CFU counts with levels of 16S rRNA is delayed, often by
several days. Most mRNAs are very unstable, with a short half-life
(18, 19). Thus, the presence of mRNA is usually indicative
of the continuous transcription of a gene. Patel et al. (31)
used reverse transcription (RT)-PCR to examine the viability of
heat-killed M. leprae and detected dnaK mRNA only
in living cells. Recently, Hellyer et al. (15) found that
exposure of log-phase M. tuberculosis to isoniazid and
rifampin for 24 h reduced the levels of fbpB (85B,
-antigen) mRNA to <4 and <0.01%, respectively, of those in the
drug-free control. A recent study has also shown that mRNA for the 85 antigen is present in vivo in persistent organisms (29).
Similarly, in other bacteria, mRNA is not detected in cells killed by
heat and other experimental treatments (32). Because of its
short half-life, mRNA rapidly disappears from dead cells, and so its
detection provides a useful indicator of cellular viability and
metabolic activity.
It has been suggested by Wayne (34) that M. tuberculosis can adapt to microaerophilic or anaerobic conditions
and can persist in a stationary phase for long periods of time.
However, this microaerophilic stationary-phase culture model contains
different populations of persistent organisms (35). To study
populations of persisters which are tolerant to antibiotics, we have
used both (i) an in vitro microaerophilic stationary-phase model
(34) in which we treat M. tuberculosis with
high-dose rifampin and (ii) a pyrazinamide-induced model in mice (the
Cornell model) (25). Rifampin and pyrazinamide were chosen
since they are the two antituberculosis drugs with the greatest ability
to kill persisting bacilli during the treatment of pulmonary
tuberculosis (27, 28). We show here that persistent bacteria
have transcriptional activity which indicates an active, though
possibly restricted, metabolism.
 |
MATERIALS AND METHODS |
M. tuberculosis growth; estimation of viability and
incorporation of [3H]uridine after rifampin treatment.
M. tuberculosis was grown in 7H9 medium containing 0.05%
Tween 80 supplemented with 10% albumin dextrose complex (Difco
Laboratories, Detroit, Mich.) without shaking for 100 days. To obtain
evenly dispersed cultures prior to experimental treatment, clumps in the cultures were broken up by vortexing the cultures in the presence of 2-mm-diameter glass beads (Philip Harris Scientific, Staffordshire, United Kingdom) for 5 min, followed by sonication in a water bath sonicator (Branson Ultrasonic B.V.) for 5 min. After addition of
rifampin at a final concentration of 100 µg ml
1, the
cultures were incubated at 37°C for 5 days. Viability was estimated
initially and at daily intervals. The cells were washed by
centrifugation three times with phosphate-buffered saline and finally
resuspended to the original volume in 7H9 broth. For CFU counts, three
100-µl samples from the appropriate serial 10-fold dilutions were
plated onto three one-third segments of plates of 7H11 agar medium
supplemented with oleic albumin dextrose complex (Difco). Before
rifampin treatment, the plates were usually inoculated from the
10
3 and 10
4 dilution. After addition of
rifampin, the neat washed culture (1 ml) was plated. Colonies were
counted after incubation of the plates in plastic bags for 3 weeks at
37°C. Broth counts were performed as serial 10-fold dilutions from
each of which triplicate 1-ml samples were added to 9 ml of 7H9 medium.
At 10-day intervals over a 2-month period of incubation at 37°C, the
broth cultures were examined for visible turbidity. Growth of M. tuberculosis in turbid tubes was confirmed by colonial morphology
on 7H11 agar plates. The most probable number of viable bacilli was
then estimated from the patterns of positive and negative tubes
(13). The absence of bacteria other than mycobacteria from
the washed cultures was shown by plating on blood agar medium. For
incorporation of radioactive uridine, 10 ml of the culture for each
time point was washed to remove the remaining rifampin, then
resuspended in 10 ml of 7H9 medium, and incubated with
[3H]uridine (10 µCi ml
1) for 20 h.
[3H]uridine (10 µCi ml
1) was also added
to the washed culture, which was further incubated in the presence of
rifampin for 20 h. RNA was extracted as described below;
[3H]uridine incorporation into total RNA was determined
as counts per minute of trichloroacetic acid-precipitated RNA.
Cornell mouse model.
M. tuberculosis was grown in
BALB/c mice weighing 18 to 20 g which were infected intravenously
with 2 × 105 CFU of a mouse-passaged, virulent H37Rv
strain of M. tuberculosis. Spleens and lungs were removed
rapidly after sacrifice, and sterile autopsy was performed at a time
point designated week
2; portions of the organs were immediately
frozen in liquid N2 for subsequent RNA extraction. CFU
counts of viable M. tuberculosis were estimated by grinding
half of the spleen and lungs in 5 ml of sterile water in motor-driven
polytetrafluorethylene-glass grinders. CFU counts were estimated from
serial 10-fold dilutions of the homogenate on plates of selective 7H11
medium (Difco), incubated at 37°C for 3 to 4 weeks. At 2 weeks after
infection (week 0), a sample of four mice yielded 2 × 107 to 5 × 107 CFU/lung or spleen.
Treatment was then given for 14 weeks with 1,000 mg of pyrazinamide and
25 mg of isoniazid per kg of body weight in the pelleted diet, after
which the sterile state was reached. Six mice were sacrificed at week 7 to monitor CFU counts. Another eight mice were then sacrificed at week
14; and the organ homogenates were cultured in selective Kirchner
liquid medium for 4 weeks, with subsequent subculturing onto selective
Löwenstein-Jensen slopes for a further 4 weeks. At each time
point, one-fifth portions of half of each of the organs were
immediately frozen in liquid N2 for subsequent RNA
extraction. Culture media were made selective for M. tuberculosis by the addition of 200 U of polymyxin B
ml
1, 100 µg of carbenicillin ml
1, 20 µg
of trimethoprim ml
1, and 10 µg of amphotericin B
ml
1. After a further 8 weeks during which each of the
remaining mice received 0.5 mg of hydrocortisone acetate together with
chloramphenicol in the drinking water at 50 mg/kg, 21 of 23 mice
yielded positive spleen and lung cultures.
RNA extraction.
Total RNA was extracted from in vitro
cultures by the method of Mangan et al. (23). Mycobacterial
RNA extraction from organs was performed on individual portions of each
organ that had been separately stored frozen in liquid nitrogen by the
method of Butcher et al. (2), but employing a prior
differential tissue lysis using a reciprocal shaker and 1-mm beads
(Hybaid Ltd., Teddington, United Kingdom) (23). RNA was
treated with RNase-free DNase I (Life Technologies) to remove
contaminating genomic DNA.
Nucleotide sequence accession number.
Gene annotation was
according to Cole et al. (3). GenBank accession numbers and
nucleotide positions are given for the genes from which PCR primer
pairs were designed to be in the coding regions: 16K
(AL021899, nucleotides [nt] 16796 to 17230; hspX, Rv2031c), 16S (X52917, nt 1471844 to 1473380;
rrnS), sigA (Z96072; nt 21832 to 23418; Rv2703),
sigB (Z96072; nt 26458 to 27429; Rv2710), dnaK
(Z95324; nt 1526 to 1800; Rv0350), and rpoB (Z95972, nt 9875 to 13393; Rv0667). The sequences of the oligonucleotides are as
follows: 16K, 5'-GAAGACGAGATGAAAGAGGGG-3' and
5'-GTAAGAATGCCCTTGTCGTAGG-3'; 16S,
5'-GCCTGGGAAACTGGGTCTAA-3' and
5'-TCTCCACCTACCGTCAATCC-3'; rpoB,
5'-GTTCGGGGAGATGGAGTGCT-3' and
5'-CGTTGCGGGACAGATTGATT-3'; sigB,
5'-AGATCAACGACCTGCTGGAA-3' and
5'-GGGACAGCCCGAATAGTTTG-3'; sigA,
5'-CCAGCACGAAGCCGCAAC-3' and
5'-TCATCCCAGACGAAATCACC-3'; dnaK,
5'-ATTGTGCACGTCACCGCCAA-3' and
5'-ACCGCGGCATCAACCTTGTT-3'. The sensitivity of these primers
was determined by measuring their ability to detect M. tuberculosis chromosomal DNA in a DNA PCR. A series of 10-fold
dilutions of known concentrations of M. tuberculosis DNA was
subjected to PCR amplification with each pair of primers. The
sensitivity of the primers was defined as the endpoint of DNA
concentration at which the primers could produce product.
RT of RNA samples and PCR.
Total RNA was reverse transcribed
essentially as described previously (2) in a total volume of
20 µl containing 0.5 mM each dATP, dCTP, dGTP and dTTP, 2.5 µM
reverse primer, 5 mM dithiothreitol, 40 U of RNAsin (Promega), 50 mM
Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, and 200 U of
Superscript II (Life Technologies). The RNA was denatured at 85°C for
5 min and then chilled on ice. After addition of the reaction mixture,
the RT reaction was carried out at 42°C for 60 min. PCR was performed
in a final volume of 50 µl which contained 10 µl of cDNA template,
using Taq DNA polymerase (Promega). The reaction mixture
contained 1 µM each primer. PCR amplification was carried out for 40 cycles (94°C for 1 min, 58°C for 2 min, and 72°C for 3 min). Each
RT-PCR was repeated twice or, for some genes, three times. A limited
choice of genes was available due to severely limited amounts of input
RNA from these models of persistence. Each RT reaction mixture
contained the equivalent RNA from one-fifth of one lung. A 20-µl PCR
sample from each reaction was subjected to electrophoresis on a 1.5% agarose gel containing ethidium bromide. Non-reverse-transcribed PCR
controls indicated absence of contaminating genomic DNA and that PCR
products derived from mRNA.
 |
RESULTS |
Isolation of in vitro persistent M. tuberculosis.
To
establish the experimental conditions necessary to select
subpopulations of in vitro microaerophilic stationary-phase bacteria that persist during exposure to antibiotic, several preliminary experiments were performed to determine the optimal concentration of
rifampin required, duration of exposure, and age of culture (Fig. 1).
The log-phase (4-day) cultures (10 ml, 3.9 × 107 CFU
ml
1; used as a control for viability) and
stationary-phase (30-day [10 ml, 1.12 × 108 CFU
ml
1] and 100-day [10 ml, 8.5 × 106
CFU ml
1]) cultures were incubated with 1, 10, 50, and
100 µg of rifampin ml
1, for 5 days. Then the cultures
were washed and resuspended in 7H9 broth to the original volume.
Viability (CFU) was examined with 1 ml of each 10-ml culture as
described in Materials and Methods. As shown in Fig.
1, rifampin at 50 µg ml
1
significantly reduced the CFU counts of stationary-phase cultures and
reduced the CFU counts of the log-phase culture to zero. Treatment with
100 µg of rifampin ml
1 resulted in CFU counts of zero
in all plate cultures.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of different concentrations of rifampin on the
viability of log-phase and stationary-phase cultures of M. tuberculosis H37Rv. Log-phase (4-day) and stationary-phase (30- and 100-day) cultures were incubated with 1, 10, 50, and 100 µg of
rifampin ml 1 for 5 days. After washing of the cultures,
viability was estimated by examination of CFU counts. Values shown are
averages of three independent experiments.
|
|
To investigate whether all populations of the bacilli in these cultures
were killed by 100 µg of rifampin ml
1, resuscitation
with fresh 7H9 broth was carried out as described in Materials and
Methods in an effort to recover any remaining viable bacilli. As shown
in Table 1, broth dilution counts
revealed that 0.085, 85, and 850 cells per ml remained after rifampin
treatment of 4-, 30-, and 100-day cultures, respectively, indicating
that a significant subpopulation from the 100-day cultures persists in
the presence of rifampin.
To confirm that the organisms detected in the broth dilutions in Table
1 were derived from viable, persistent M. tuberculosis rather than contamination by other bacteria, samples from all broth
dilutions were plated onto blood agar plates, which were incubated
overnight. No other bacteria were grown. Also, the samples from all
dilutions were plated onto selective 7H11 agar plates at the end of the
2 months of incubation. All positive broth cultures produced typical
M. tuberculosis colonies, containing acid-fast organisms, on
the agar plates after 3 weeks of incubation. Negative broth cultures
showed no CFU counts. These results indicated that 100 µg of rifampin
ml
1 killed all actively replicating bacilli because only
a few bacilli survived in log-phase cultures (0.085 from 10 ml of
5 × 107 ml
1 [Table 1]). However, in
the stationary-phase cultures treated with rifampin at 100 µg
ml
1, although a 5-log killing was observed, nearly 3 logs
of bacteria remained viable by broth counts (851 from 10 ml of 5 × 107 ml
1 [Table 1]). The surviving
bacilli may be representative of organisms persisting after
chemotherapy in vivo. These persistent bacteria are plate count
negative but broth dilution count positive.
Identification of phenotypic resistance of persisters to
rifampin.
To distinguish between phenotypic and genotypic
resistance, we washed the 100-day stationary-phase persisting bacteria
three times after rifampin treatment. The washed cultures were diluted 10-fold, and 1 ml of each dilution, including the neat culture, was
added to 9 ml of 7H9 broth containing 0.1 µg of rifampin
ml
1. A normal MIC for M. tuberculosis in 7H9
medium is approximately 0.1 µg ml
1. Controls were
performed by adding 1 ml of each dilution to 9 ml of 7H9 broth without
the drug. After 2 months of incubation, no growth was observed in
rifampin-containing cultures (n = 3), indicating that
the persistent bacilli were sensitive to rifampin after they emerged
from stationary phase and started to grow in aerated, fresh broth.
Persistent bacilli resuscitated in the absence of rifampin (day 100 [Table 1]) showed viable bacilli by broth dilution counts. These
bacteria were negative for rifampin resistance mutations in
rpoB as detected both by RT-PCR followed by sequencing and hybridization with oligonucleotide probes specific for the rifampin resistance-associated mutations (Immunogenetics N.V., Rijswijk, The Netherlands) (data not shown). These data indicate that
the resistance is phenotypic in this model. This model is operationally
defined as a 100-day culture of M. tuberculosis incubated
with 100 µg of rifampin ml
1 for 5 days.
RT-PCR analysis of persistent bacilli in the in vitro persistent
model.
RT-PCR for the following genes was performed:
rpoB (encodes the rifampin target, RNA polymerase subunit
B), hspX (16-kDa protein [
-crystallin homolog]),
rrnS (16S rRNA), and sigA and sigB
(two
70 homologs) (8). sigB may be
functionally analogous to stationary-phase sigma factor gene
rpoS of E. coli (21) and to M. tuberculosis sigF (6), which is transcribed in the
stationary growth phase, but the sequences are quite divergent.
Stationary-phase M. tuberculosis is associated with
increased expression of the
-crystallin 16-kDa protein
(37). Prior to RT-PCR, we determined the sensitivity of
primers for the genes described in Materials and Methods.
sigA-specific primers are able to detect 107
M. tuberculosis gene copies, the 16S rRNA primer can detect
105 gene copies, and the rest of the primers can detect
106 gene copies. Thus, RT-PCR cannot generate products with
the specific primers from the samples containing fewer than
105, 106, or 107 copies of
templates, respectively. Total RNA was extracted from the same volume
of cultures before and after rifampin treatment in the in vitro
persistent model, and this was used for RT-PCR. Figure
2a shows that all of these genes are
transcribed in vitro in stationary-phase bacilli. After 5 days of
rifampin treatment, which reduced the CFU to zero (Fig. 2b), the 16S
rRNA was not diminished and transcripts for rpoB,
16K, and sigB could still be detected, albeit at
reduced levels, while the transcript for sigA was not seen.
The sequences of the sigA, sigB, and
hspX PCR products were verified as M. tuberculosis in origin by commercial sequencing (Cambridge
BioScience Ltd., Cambridge, United Kingdom).




View larger version (197K):
[in this window]
[in a new window]
|
FIG. 2.
Detection of mRNA in M. tuberculosis H37Rv by
RT-PCR before and after treatment with antituberculosis agents in vitro
and in vivo. (a) RNA was extracted from 100-day cultures before
rifampin treatment (106 CFU per RT reaction). (b) After
rifampin (100 µg/ml) treatment for 5 days (0 CFU; same volume of
culture used for RT as in panel a). (c) RNA was extracted from infected
mice before antituberculosis drug treatment; week 0 (106
CFU per RT). (d) After antituberculosis drug treatment in mice; week 14 (0 CFU; same volume of tissue used for RT as in panel c). (e) The
100-day cultures were treated with rifampin (100 µg/ml) for 5 days.
The cells were washed three times to remove rifampin and then incubated
with 7H9 broth for 12 h. RT-PCR was performed with
sigA, sigB, rpoB, and 16K
primers before (R) and after (7H9) resuscitation with 7H9 medium. (f)
The 100-day cultures were treated with rifampin for 5 days, washed free
of rifampin, and immediately heat shocked at 45°C for 30 min compared
to incubation at 37°C for 30 min. Detected genes are shown above
lanes; the PCR product sizes are as follows: sigA, 306 bp;
sigB, 273 bp; rpoB, 307 bp; dnaK, 275 bp; 16K (hspX), 242 bp; 16S, 336 bp.
10 1, 5 × 10 1, 10 2, and
10 3 indicate that 10-, 50-, 100-, and 1,000-fold-diluted
cDNAs were used for PCR. N, DNase I-treated RNA but no RT enzyme. ,
PCR control with each primer and 10 µl of water instead of template.
The following limits of detection (gene copies) were estimated by DNA
PCR: 16S, 105 (equivalent to 100 CFU of a
log-phase growth culture); sigA, 107;
sigB, 106; 16K, 106;
rpoB, 106; dnaK, 106
(equivalent to ~104 CFU).
|
|
To provide further evidence that the mRNA present in persistent bacilli
was derived from metabolically active bacilli rather than from dead
cells, RNA was extracted from a 100-day culture which was first killed
by heating at 80°C for 30 min followed by incubation of the cultures
at room temperature for 24 h to ensure complete degradation of the
mRNA. RT-PCR was performed to detect hspX, sigA,
and sigB mRNAs and 16S rRNA. No hspX,
sigA, or sigB mRNA was detected in the
heat-killed culture; however, the 16S rRNA was still detectable,
indicating its relative stability. Results for sigB mRNA and
16S rRNA are shown in Fig. 3. No viable counts were obtained from the heat-killed culture, as determined by
both plate counts and broth dilution counts. RT-PCR was also performed
with RNA extracted from H2O2 (20 mM for 10 h)- and acetic acid (pH 3.5 for 10 h)-killed bacilli. No mRNA was
detected in these killed bacteria, while 16S rRNA remained unchanged
(data not shown). These results confirmed that mRNA is a good correlate of viability compared to rRNA and that mRNA detected in
rifampin-treated cultures was derived from living persistent organisms.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 3.
mRNA as a correlate of viability, analyzed by limiting
dilution RT-PCR of heat-killed and viable 100-day cultures of M. tuberculosis. (a) sigB mRNA; (b) 16S rRNA. Lanes N and
, as in Fig. 2; lane M, molecular weight markers.
|
|
Persistent bacilli are environmentally responsive.
Further
confirmation that persistent bacilli are alive and retain the potential
for rapid metabolic responses to environmental change came from the
examination of mRNA from rifampin-treated cultures to which fresh 7H9
medium was added. As shown in Fig. 2e, the levels of the
hspX, rpoB, and sigA mRNAs increased
5- to 10-fold after 12 h of resuscitation. In Fig. 2e, strong
sigA and sigB signals were observed at
10
1 dilution, but the signal at the 10
2
dilution was unexpectedly low. This emphasizes that RT-PCR is, at best,
only semiquantitative. RT-PCR was performed to detect dnaK
mRNA after the bacilli were exposed to elevated temperature. Total RNA
was extracted from the washed cultures before and immediately after
heat shock at 45°C for 30 min. As shown in Fig. 2f, dnaK mRNA was detectable from the persistent bacilli at 37°C. In a temperature shift from 37 to 45°C, dnaK mRNA increased
10-fold, indicating that these persistent bacilli were responsive to
heat shock.
Incorporation of [3H]uridine by persistent
bacilli.
We performed an assay to measure the incorporation of
[3H]uridine into RNA as a correlate of metabolic and
transcriptional activity in persistent bacilli. So as to be able to
accurately compare uridine uptake rates between low numbers of
persisting bacteria in a rifampin-treated culture with the uptake rate
of rapidly growing bacteria, the quantitative relationship between bacterial numbers and uridine incorporation was determined. Log-phase (4 days with an initial count of 1.12 × 106 CFU
ml
1) and stationary-phase (100 days with an initial count
of 1.21 × 106 CFU ml
1) cultures were
serially diluted in fivefold steps and incubated in the absence of
rifampin with [3H]uridine (10 µCi ml
1)
for 20 h (Fig. 4). [3H]uridine incorporation was
proportionally reduced as the cell numbers decreased as shown in Fig.
4. Above bacterial cell densities of 2 log10 CFU ml
1, the incorporation of
[3H]uridine into RNA by 100-day cultures is approximately
15% of the 4-day culture values for the same number of viable
organisms (CFU counting). This indicates active but reduced metabolism
in stationary-phase bacteria.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Kinetic analysis of [3H]uridine
incorporation by log-phase and stationary-phase M. tuberculosis. Log-phase (4-day) and stationary-phase (100-day)
cultures were serially diluted fivefold. [3H]uridine was
added to the cultures, and RNA was extracted after 20 h of
incubation. The results were confirmed in three independent
experiments.
|
|
To measure uridine uptake rates in the subpopulation of
rifampin-treated persisting organisms, we performed a series of
experiments (Table 2) in which rifampin
was added to a 100-day culture (6.6 × 105 CFU
ml
1) at a final concentration of 100 µg
ml
1 for 5 days. At 1-day intervals, a sample of the
culture was washed and incubated with [3H]uridine (10 µCi ml
1). [3H]uridine was also added to a
5-day rifampin-treated culture in the presence of the drug; heat-killed
(80°C for 30 min) cultures were included as background control.
Viability was estimated by CFU counts and broth dilution counts. As
shown in Table 2, after 1 to 5 days of rifampin treatment, the CFU
counts were reduced to zero, but about 103 cells
ml
1 (2.93 log10 at 95% confidence limits;
2.29 to 3.51) remained from 3.8 × 107 cells
ml
1 (7.45 log10; 6.17 to 8.73) at day 5, as
estimated by triplicate broth counts. This result agrees with the
100-day culture viability data in Table 1 and confirms the existence of
a subpopulation of persisters in this model.
In the presence of rifampin, the persistent bacilli incorporated 338 cpm of [3H]uridine (518
180 cpm background
[heat-killed control]) (Table 2). The ratio between the
[3H]uridine incorporation of persisters (at 5 days) and the incorporation of log-phase organisms (from the linear
range in Fig. 4) is 338/968,500 = 3.490 × 10
4.
The corresponding ratio between the broth counts of persisters and the
plate counts of log-phase organisms is 1.73 × 103/1.12 × 106 = 1.545 × 10
3. This indicates that the persisters were
incorporating uridine at about one-quarter [3.490/(1.545 × 10) = 0.23] of the rate of the same number of log-phase bacteria.
This agrees fairly well with data derived from Fig. 4, in which the
incorporation of [3H]uridine into stationary-phase
cultures was about 15% of that in log-phase cultures. Thus, the
rifampin persisters have uridine uptake rates similar to those of the
bulk of the stationary-phase bacilli and represent a subpopulation of
bacilli in stationary-phase cultures.
Broth counts and CFU counts are equivalent in log-phase cultures but
vary by nearly 1.7 logs in 100-day cultures (Table 2). This difference
in 100-day cultures probably reflects presence of the subpopulation of
persisters (described above) that are CFU negative. After resuscitation
of persisters with fresh 7H9 medium, irrespective of the duration of
treatment with rifampin (1 to 5 days), the incorporation of
[3H]uridine by persisters increased by 82%, from 338 to
2,156 cpm (average of 2,336, minus background of 180), a
transcriptional activity similar to that for log-phase growth. This
indicated that the persisters were viable, with reduced metabolic and
transcriptional activity, and rapidly reinitiated growth in fresh
broth, as measured both by increased uridine uptake and increased
levels of mRNA (Fig. 2e).
RT-PCR analysis of persistent bacilli in the Cornell model.
To
establish whether a similar situation exists in vivo, we chose the
murine Cornell model. In our experiments (Fig.
5), the lungs and spleens of the mice had
high plate viable counts before antibiotic treatment and low counts
after 44 days of treatment. They reached a sterile state with negative
lung and spleen cultures on solid and liquid media at 14 weeks, when
treatment was completed. Since it was difficult to measure the
concentration of bacterial RNA extracted from mouse lungs and spleens
which were M. tuberculosis culture negative after 14 weeks
of chemotherapy, we used RNA extracted from equal volumes of mouse
organs before and after chemotherapy for RT-PCR. RT-PCR of RNA from
acutely infected lungs (5 × 107 CFU/lung [Fig. 5])
removed before treatment revealed transcripts for rpoB,
sigA, sigB, 16K, and 16S rRNA (Fig.
2c). Significantly, bacterial mRNA for sigB,
rpoB, and 16K was detected in lungs after 14 weeks of chemotherapy, and the level of 16S rRNA was reduced, as seen
by RT-PCR at 10
2 dilution (Fig. 2d), compared to the
prechemotherapy level. The sigA transcripts were not
detectable in either in vitro persisters or mouse persisters (Fig. 2c
and d, lanes sigA 10
1), probably due to low
numbers of bacteria (see Discussion). The rpoB lanes showed
multiple low-molecular-weight bands with no detectable correct-size
band. Also in Fig. 2c, the 16S signal was stronger in 10
2
dilution than that in 10
1 dilution. These aberrant
results may be due to the interference of residual mouse RNA with the
RT-PCR. RT-PCR was also performed with the RNA extracted from spleens;
the patterns of RT-PCR amplification were similar to those of the
lungs. Here only the lung data are presented. All lungs and spleens
used for RT-PCR after the 14-week chemotherapy treatment were
preconfirmed as culture negative determined by CFU counts and broth
inoculation counts. RT-PCR was also performed with RNA extracted from
noninfected mouse lungs as a control for cross-reaction with mouse RNA.
No PCR products were amplified (data not shown). The sequence of the
hspX PCR product was verified as described above. All
controls were performed to ensure that RT-PCR products derived from
mRNA and not from residual genomic DNA in the RNA preparation (Fig. 2,
lanes N). The entire in vivo experiment was undertaken twice with the
same results each time; in the second experiment, the RT-PCR was
performed blind by two different workers who obtained the same results.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 5.
Viability of M. tuberculosis H37Rv in vivo
before and after treatment with antituberculosis agents in the mouse
Cornell model. The results of a single experiment are shown, with
viability expressed as log CFU counts per organ (spleen or lung). Mice
were infected intravenously at week 2, and the infection allowed to
progress for 2 weeks prior to treatment with pyrazinamide and isoniazid
for 14 weeks (weeks 0 to 14). At week 14, 2 mice yielded a positive
organ culture, one for lung only (1/8 lung +ve) and one for spleen only
(1/8 spleen +ve). The remaining 6 mice at week 14 + 1 were all
culture negative, and their spleens and lungs were frozen in one-fifth
portions for RNA extraction and RT-PCR analysis. Not shown is the
bacteriological relapse in 21 of 23 mice after steroid treatment given
at week 14 + 8, indicating restoration of culturability and hence
rescue from dormancy.
|
|
 |
DISCUSSION |
We have used two models of phenotypic persistence in M. tuberculosis to measure mRNA transcripts by RT-PCR in order to
investigate the transcriptional activity and hence the physiological
state of persistent bacilli. In the first model, the organisms are
cultured long term in a microaerophilic gradient (34), where
the stationary-phase organisms are viable; they are resistant to the
MIC of rifampin (0.1 µg ml
1). While log-phase bacilli
are very sensitive to antituberculosis agents, stationary-phase
bacteria are partially tolerant to these drugs (7, 27, 35),
and a subpopulation of persistent bacilli are not killed by any known
antituberculous agents (28). The rationale for the in vitro
approach taken in this study was to treat microaerophilic
stationary-phase cultures with rifampin, which kills the replicating
bacilli; the organisms which remain after chemotherapy (~0.005%) we
term persisters. To start with, we established the correct conditions
for the assay, in particular, the concentration of rifampin and the
duration of chemotherapy. To avoid the generation of genetic resistance
by selective pressure (12) during the experiments, we used
high doses of the antibiotic for short periods of time. Rifampin is
particularly suitable since it is bactericidal and starts killing
M. tuberculosis within an hour of exposure. Importantly, it
is one of the most active sterilizing drugs for chemotherapy of
tuberculosis (28). We treated the stationary-phase bacteria
with a high level of rifampin (100 µg ml
1) which
reduces plate counts to zero but results in a small number of
persisting organisms which are detectable and quantifiable (13) by broth dilution counting. The second model is murine chronic tuberculosis, which is induced by chemotherapy (Cornell model
[25]). Mice are infected with M. tuberculosis and then treated for 14 weeks with high-dosage
pyrazinamide (one of the most active sterilizing drugs) and isoniazid,
which reduce the broth and plate counts in the spleens and lungs to
zero (Fig. 5). However, mice in this sterile state contain large
amounts of M. tuberculosis DNA, which is estimated to be
equivalent to 105 bacteria per organ (5). Upon
treatment of mice with steroids, spleens and lungs become culture
positive again, indicating reactivation from a nonculturable and
drug-insensitive (tolerant) state. Both models mirror chemotherapy and
subsequent relapse of tuberculosis in humans.
In the in vitro persistent model, RNA was detected from bacilli which
survived the treatment with rifampin. The mRNA detected was not from
dead bacilli since it disappeared from dead organisms (Fig. 3). We have
previously measured the half-lives of mRNA in both log-phase and
long-term stationary-phase M. tuberculosis cultures and
shown them to be growth phase independent, between 2 and 3 min for
16K and sigB and >40 min for sigA
(18, 19). We also compared the kinetics of loss of RT-PCR
signals between 4-day and 30-day cultures. There was no difference of
RT-PCR signal loss between log-phase and stationary-phase cultures
(data not shown). Thus, it is unlikely that the RT-PCR results (Fig.
2b) are accounted for by long-term stable mRNA. These results suggest that ongoing transcriptional (metabolic) activity is retained in
persistent organisms. Although sigA mRNA is constitutively transcribed and has a long half-life (19), it is not
detected in persistent bacilli. This result is most likely due to the
low sensitivity of the primers in specimens with low bacilliary load so
that the sigA mRNA transcripts become undetectable. The
limit of detection by DNA PCR for sigA was 107
genome equivalents, at least a logfold less sensitive than for the
other mRNA transcripts (see the legend to Fig. 2). Alternatively, the
transcription of sigA might be turned off in these
persistent organisms. The data cannot distinguish between these
possibilities at such low bacillary counts. Importantly, the persistent
organisms incorporated [3H]uridine into RNA even in the
presence of a high concentration of rifampin, which confirmed the
RT-PCR data and indicated that active transcription took place in these
persistent bacilli but at a reduced rate.
The persisters were very responsive to changes in their environment.
Upon resuscitation of 100-day rifampin-treated cultures with fresh 7H9
medium, transcription of the bacilli increased within 12 to 20 h,
as demonstrated by 5- to 10-fold increases in mRNA by RT-PCR (Fig. 2e)
and by 5-fold increases in incorporation of [3H]uridine
into M. tuberculosis RNA (Table 2). The transcription of
dnaK increased in a temperature shift from 37 to 45°C
(Fig. 2f). These results indicate that the in vitro persisters not only were metabolically active but also retained their potential for environmental responsiveness.
Whether bacilli which persist in human tuberculosis infection and in
murine chronic animal models are metabolically active has been a
crucial open question for many years (10, 11). Although PCR
amplification of dormant M. tuberculosis DNA in the Cornell
model indicated the presence of ~105 genome equivalents
per lung or spleen (5), it has not been possible to
distinguish between dead bacilli and living organisms. A recent study
(29) has shown mRNA for 85 antigen can be detected in viable
but none culturable bacilli in the Cornell model, indicating that the
persistent bacteria are transcriptionally active. Here we show that
some of the M. tuberculosis mRNA (hspX and
sigB) was detectable in mouse tissues which were negative
for tubercle bacilli by CFU counts and broth inoculation counts after
14 weeks of chemotherapy (the sterile state). It is surprising to find any mRNA at all after 14 weeks of chemotherapy since mRNA is highly labile and depleted within killed bacilli within a very short time
(18, 19). Since it was not experimentally possible to measure the half-lives of these mRNAs or the incorporation of [3H]uridine into RNA in the infected mouse, we cannot
discriminate between active transcription of unstable mRNA and stable
mRNAs in Cornell model persisters. Nevertheless, the data suggest that substantial numbers of nonculturable persistent bacilli are present in
infected tissues postchemotherapy. These bacteria may be metabolically active because they contain mRNA and rRNA. The data for the Cornell model parallel those for the in vitro long-term stationary
microaerophilic model and argue strongly for the hypothesis that
M. tuberculosis can adapt to a nonculturable yet
metabolically active state in which mRNA is detected and low levels of
active transcription may be measured. We propose that some form of an
adaptive gene expression response, yet to be characterized, allows a
subpopulation of bacteria to persist within the host without being
killed and that this state confers resistance to high concentrations of
antimycobacterial agents. Thus, persisting M. tuberculosis
may exist in some physiological form in which limited metabolism
occurs, presumably with little or no cell turnover, accounting for
tolerance to conventional antibiotic treatment. The mechanism of
tolerance to rifampin (a transcriptional inhibitor) has not been
investigated. It has been shown that tubercle bacilli incubated under
long-term microaerophilic and anaerobic conditions developed a very
thick cell wall outer layer (4). A change in drug
permeability may be one of the possible mechanisms of bacterial
tolerance to antibiotics. In addition, the use of alternative sigma
factors (such as SigB) in the persistent state might confer
differential sensitivity of the RNA polymerase holoenzyme to rifampin
as shown for E. coli (36), thus allowing
continued but modified transcription. In this state, active
transcription continues since labile mRNA is detectable and uridine
incorporation into RNA continues even in the presence of rifampin.
These persisting bacilli also maintain their environmental
responsiveness (Fig. 2e and f) necessary for regrowth.
The recent demonstration that HSP-65 DNA vaccination could suppress
bacteriological relapse in M. tuberculosis-infected mice after 12 weeks of chemotherapy (22) and the relapse rate for tuberculosis of 2 to 5% per annum in AIDS patients suggests an important role for immunity in the maintenance of persistence. The
experiments described here provide an approach to study gene expression
associated with persistence as well as to investigate the mechanisms of
antibiotic tolerance (phenotypic resistance) in persisters.
Furthermore, since antimicrobial agents require some level of bacterial
metabolism to be effective, a scientific rationale has now been
provided for the development of chemotherapeutic agents which inhibit
transcription in persisters. Such agents should be able to kill
organisms persisting in the presence of rifampin or pyrazinamide, the
most actively sterilizing of current drugs (28), and
therefore substantially shorten the course of the chemotherapy of human
tuberculosis. They might also be useful for the chemoprophylaxis of
latent bacilli, which currently infect one-third of the world's population.
We thank the British Medical Research Council for financial
support (grants G9328099, G9814061, and G9525858) and The Sanger Centre
for bioinformatics support prior to completing and making available the
M. tuberculosis genome sequence.
| 1.
|
Bloom, B. R., and J. D. McKinney.
1999.
The death and resurrection of tuberculosis.
Nat. Med.
5:872-874[CrossRef][Medline].
|
| 2.
|
Butcher, P. D.,
J. A. Mangan, and I. M. Monahan.
1998.
Intracellular gene expression: analysis of RNA from mycobacteria in macrophages using RT-PCR.
Methods Mol. Biol.
101:285-306[Medline].
|
| 3.
|
Cole, S. T.,
R. Brosch,
J. Parkhill,
T. Garnier,
C. Churcher,
D. Harris,
S. V. Gordon,
K. Eiglmeier,
S. Gas,
C. E. Barry III,
F. Tekaia,
K. Badcock,
D. Basham,
D. Brown,
T. Chillingworth,
R. Connor,
R. Davies,
K. Devlin,
T. Feltwell,
S. Gentles,
N. Hamlin,
S. Holroyd,
T. Hornsby,
K. Jagels,
A. Krogh,
J. McLean,
S. Moule,
L. Murphy,
K. Oliver,
J. Osborne,
M.-A. Rajandream,
J. Rogers,
S. Rutter,
K. Seeger,
J. Skelton,
R. Squares,
S. Squares,
J. E. Sulston,
K. Taylor,
S. Whitehead, and B. G. Barrell.
1998.
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature
393:537-544[CrossRef][Medline].
|
| 4.
|
Cunningham, A. F., and C. L. Spreadbury.
1998.
Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton -crystallin homolog.
J. Bacteriol.
180:801-808[Abstract/Free Full Text].
|
| 5.
|
De Wit, D.,
M. Wootton,
J. Dhillon, and D. A. Mitchison.
1995.
The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis.
Tuber. Lung Dis.
76:555-562[CrossRef][Medline].
|
| 6.
|
DeMaio, J.,
Y. Zhang,
C. Ko,
D. B. Young, and W. R. Bishai.
1996.
A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis.
Proc. Natl. Acad. Sci. USA
93:2790-2794[Abstract/Free Full Text].
|
| 7.
|
Dickinson, J. M., and D. A. Mitchison.
1981.
Experimental models to explain the high sterilizing activity of rifampicin in the chemotherapy of tuberculosis.
Am. Rev. Respir. Dis.
123:367-371[Medline].
|
| 8.
|
Doukhan, L.,
M. Predich,
G. Nair,
O. Dussurget,
I. Mandic-Mulec,
S. T. Cole,
D. R. Smith, and I. Smith.
1995.
Genomic organization of the mycobacterial sigma gene cluster.
Gene
165:67-70[CrossRef][Medline].
|
| 9.
|
Dupray, E.,
M. P. Caprais,
A. Derrien, and P. Fach.
1997.
Salmonella DNA persistence in natural seawaters using PCR analysis.
J. Appl. Microbiol.
82:507-510[CrossRef][Medline].
|
| 10.
|
Gangadharam, P. R. J.
1995.
Mycobacterial dormancy.
Tuber. Lung Dis.
76:477-479[CrossRef][Medline].
|
| 11.
|
Grange, J. M.
1992.
The mystery of the mycobacterial `persistor.'
Tuber. Lung Dis.
73:249-251[CrossRef][Medline].
|
| 12.
|
Guillemot, D.,
C. Carbon,
B. Balkau,
P. Geslin,
H. Lecoeur,
F. Vauzelle-Kervroedan,
G. Bouvenot, and E. Eschwege.
1998.
Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.
JAMA
279:365-370[Abstract/Free Full Text].
|
| 13.
|
Fisher, R. A., and F. Yates.
1963.
Statistical tables for biological, agricultural and medical research, Table VIII2, p. 66.
Oliver and Boyd, Edinburgh, United Kingdom.
|
| 14.
|
Fox, W.
1981.
Whither short-course chemotherapy?
Br. J. Dis. Chest
75:331-357[CrossRef][Medline].
|
| 15.
|
Hellyer, T. J.,
L. E. DesJardin,
G. L. Hehman,
M. D. Cave, and K. D. Eisenach.
1999.
Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis.
J. Clin. Microbiol.
37:290-295[Abstract/Free Full Text].
|
| 16.
|
Herman, L.
1997.
Detection of viable and dead Listeria monocytogenes by PCR.
Food Microbiol.
14:103-110.
|
| 17.
|
Hong Kong Tuberculosis Treatment Services and East African and British Medical Research Councils.
1976.
First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a shortcourse regimen.
Lancet
1:162-163[CrossRef][Medline].
|
| 18.
|
Hu, Y., and A. R. M. Coates.
1999.
Transcription of the stationary-phase-associated hspX gene of Mycobacterium tuberculosis is inversely related to synthesis of the 16-kilodalton protein.
J. Bacteriol.
181:1380-1387[Abstract/Free Full Text].
|
| 19.
|
Hu, Y., and A. R. M. Coates.
1999.
Transcription of two sigma 70 homologue genes, sigA and sigB, in stationary-phase Mycobacterium tuberculosis.
J. Bacteriol.
181:469-476[Abstract/Free Full Text].
|
| 20.
|
Kochi, A.
1991.
The global tuberculosis situation and the new control strategy of the World Health Organisation.
Tubercle
72:1-6[CrossRef][Medline].
|
| 21.
|
Lange, R., and R. Hengge-Aronis.
1991.
Identification of a central regulator of stationary-phase gene expression in Escherichia coli.
Mol. Microbiol.
5:49-59[Medline].
|
| 22.
|
Lowrie, D. B.,
R. E. Tascon,
V. L. D. Bonata,
V. M. F. Lima,
L. H. Faccioli,
E. Stravropoulos,
M. J. Colston,
R. G. Hewinson,
K. Moelling, and C. L. Silva.
1999.
Therapy of tuberculosis in mice by DNA vaccination.
Nature
400:269-271[CrossRef][Medline].
|
| 23.
|
Mangan, J. A.,
K. M. Sole,
D. A. Mitchison, and P. D. Butcher.
1997.
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria.
Nucleic Acids Res.
25:675-676[Abstract/Free Full Text].
|
| 24.
|
Masters, C. I.,
J. A. Shallcross, and B. M. Mackey.
1994.
Effect of stress treatments on the detection of Listeria monocytogenes and enterotoxigenic Escherichia coli by the polymerase chain reaction.
J. Appl. Bacteriol.
77:73-79[Medline].
|
| 25.
|
McCune, R. M.,
F. M. Feldmann, and W. McDermott.
1966.
Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli.
J. Exp. Med.
123:469-486[Abstract].
|
| 26.
|
McKillip, J. L.,
L.-A. Jaykus, and M. Drake.
1998.
rRNA stability in heat-killed and UV-irradiated enterotoxigenic Staphylococcus aureus and Escherichia coli O157:H7.
Appl. Environ. Microbiol.
64:4264-4268[Abstract/Free Full Text].
|
| 27.
|
Mitchison, D. A., and J. B. Selkon.
1956.
The bactericidal activities of antituberculous drugs.
Am. Rev. Tuberc.
74(Suppl.):109-116[Medline].
|
| 28.
|
Mitchison, D. A.
2000.
Role of individual drugs in the chemotherapy of tuberculosis.
Int. J. Tuberc. Lung Dis.
4:796-806[Medline].
|
| 29.
|
Pai, S. R.,
J. K. Actor,
E. Sepulveda,
R. L. Hunter, Jr., and C. Jagannath.
2000.
Identification of viable and non-viable Mycobacterium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA.
Microb. Pathog.
28:335-342[CrossRef][Medline].
|
| 30.
|
Parrish, N. M.,
J. D. Dick, and W. R. Bishai.
1998.
Mechanisms of latency in Mycobacterium tuberculosis.
Trends Microbiol.
6:107-112[CrossRef][Medline].
|
| 31.
|
Patel, B. K. R.,
D. K. Banerjee, and P. D. Butcher.
1993.
Determination of M. leprae viability by the polymerase chain reaction amplification of 71kDa heat shock protein mRNA.
J. Infect. Dis.
168:799-800[Medline].
|
| 32.
|
Sheridan, G. E. C.,
C. I. Masters,
J. A. Shallcross, and B. M. Mackey.
1998.
Detection of mRNA by reverse transcription-PCR as an indicator of viability in Escherichia coli cells.
Appl. Environ. Microbiol.
64:1313-1318[Abstract/Free Full Text].
|
| 33.
|
Van der Vliet, G. M.,
P. Schepers,
R. A. Schukkink,
B. Van Gemen, and P. R. Klatser.
1994.
Assessment of mycobacterial viability by RNA amplification.
Antimicrob. Agents Chemother.
38:1959-1965[Abstract/Free Full Text].
|
| 34.
|
Wayne, L. G.
1976.
Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions.
Am. Rev. Respir. Dis.
114:807-811[Medline].
|
| 35.
|
Wayne, L. G., and H. A. Sramek.
1994.
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
38:2054-2058[Abstract/Free Full Text].
|
| 36.
|
Wegrzyn, A.,
A. Szalewska-Palasz,
A. Blaszczak,
K. Liberek, and G. Wegrzyn.
1998.
Differential inhibition of transcription from sigma70- and sigma32-dependent promotors by rifampicin.
FEBS Lett.
440:172-174[CrossRef][Medline].
|
| 37.
|
Yuan, Y.,
D. D. Crane, and C. E. Barry.
1996.
Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial -crystallin homolog.
J. Bacteriol.
178:4484-4492[Abstract/Free Full Text].
|